Sino-Shenchang is a high-end neurointerventional device developer. The company integrates R&D, production and sales. Its business covers three major fields of neurointerventional ischemia, hemorrhage and access. The products include: the world’s first NOVA intracranial drug-eluting stent System, the first domestic rapid exchange balloon Neuro RX for intracranial stenosis, and the first domestic low-named pressure rapid exchange balloon Neuro LPS for intracranial stenosis. Recently, Sino-Shenchang has received a new round of investment of RMB 100 million. The investors are Daoyuan Capital, Chengdu Biocity, Beijing Xingwen, Nolan Investment, Beth Licheng, and Shanghai Kanting.
This article is reproduced from: https://www.itjuzi.com/investevent/13639837
This site is for inclusion only, and the copyright belongs to the original author.